Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Incompetent CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Comment by Layth1990on Mar 05, 2021 2:04pm
121 Views
Post# 32729858

RE:RE:RE:RE:RE:RE:RE:Incompetent CEO

RE:RE:RE:RE:RE:RE:RE:Incompetent CEO

To he honest, nothing is guaranteed. Good phase 2 results, we got Dumped from 8.9cad to 4cad in one day. We got the best deal with nuance, then Suspecious buy before 2 days of the announcement then dumped. We are supposed to be now at 10+ after the deal. We were 8.9 at phase 2.  

investors are getting pushed away, my trust is totally gone in ceo/directors but not in the science. I come from a scientic background and i know the issue isnt from the science. We have a good nuance deal, bank full with money and fully funded phase 3. Sp 4.5 cad lol. why am i investing here thenand who said it wont get dumped even after good phase 3 results. We have seen it all! 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities